Myomo launches MyoPro 2x, enhancing independence for patients with arm and hand paralysis

Myomo launches MyoPro 2x: ©Myomo

Myomo, Inc. (NYSE: MYO), a manufacturer of wearable medical robotics, unveiled the MyoPro 2x, the newest model in its line of myoelectric orthoses designed to help individuals with upper-limb paralysis regain movement and independence.

The MyoPro 2x introduces key improvements in donning, fit, and function—areas that directly impact ease of use and clinical outcomes. With a streamlined and more intuitive method for users to put on the device independently, the company expects greater adoption and better day-to-day performance.

“Our goals for these enhancements were primarily clinical,” said Malcolm Bock, vice president of engineering and product strategy at Myomo. “The product development process was driven by inputs from users and clinicians, along with Myomo’s own product performance data.”

Updates to the MyoPro 2x include integrating common customizations into the standard design—shortening the time clinicians need to fit patients—and providing new instructional materials for both clinicians and patients. Myomo is also supporting the rollout by offering a certification process for orthotic & prosthetic providers to become MyoPro Centers of Excellence.

“The MyoPro 2x is about more than innovation—it’s about putting independence back into the hands of users,” said Myomo chairman and CEO Paul R. Gudonis. “This launch is the result of our commitment to listen to clinicians and users alike and to deliver meaningful improvements that make a real difference in daily life.”

A growing market for wearable medical robotics

The launch of the MyoPro 2x highlights Myomo’s continued expansion in the wearable medical device and robotic orthotics sector, a market that is experiencing rapid growth due to aging populations, increased prevalence of stroke and neuromuscular conditions, and technological advances in materials and sensors.

Wearable medical devices—particularly those in the rehabilitation and mobility-assist categories—are evolving beyond passive supports to actively powered exoskeletons and smart orthoses. These systems detect and respond to biological signals, such as electromyographic (EMG) activity, to provide real-time assistance and movement. Myomo’s MyoPro is one of the few FDA-registered devices that enables users with partial muscle activation to regain functional motion in their arms and hands.

According to market research firms, the global wearable medical device market was valued at over $25 billion in 2023 and is projected to grow at double-digit rates, driven in part by robotic assistive devices for post-stroke rehabilitation and chronic conditions such as ALS or multiple sclerosis. The integration of robotics with real-time biofeedback has made devices like MyoPro particularly relevant for restoring autonomy in activities of daily living.

Beyond individual patients, health care systems are increasingly embracing these technologies as cost-effective alternatives to in-patient rehabilitation. Devices that allow home use and encourage user compliance—like the MyoPro 2x—are well-positioned to meet this need.